WO2001097863A1 - PREPARATIONS FOR MEASURING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME - Google Patents
PREPARATIONS FOR MEASURING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME Download PDFInfo
- Publication number
- WO2001097863A1 WO2001097863A1 PCT/JP2001/005331 JP0105331W WO0197863A1 WO 2001097863 A1 WO2001097863 A1 WO 2001097863A1 JP 0105331 W JP0105331 W JP 0105331W WO 0197863 A1 WO0197863 A1 WO 0197863A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gastric
- measuring
- preparation
- intragastric
- labeled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1206—Administration of radioactive gases, aerosols or breath tests
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
Definitions
- the present invention relates to a technique for measuring gastric pH, specifically, a preparation for measuring gastric pH and a gastric pH measuring method using the preparation. More specifically, the present invention relates to a preparation for noninvasively measuring gastric pH using exhaled breath, and a method for measuring gastric pH using the preparation.
- H 2 -antagonists and gastric acid secretion inhibitors have greatly contributed to the treatment of gastric and duodenal ulcers.
- recurrence after treatment has become a problem, and the treatment itself has been greatly highlighted in the medical community, including a review of treatment methods for gastric ulcer and duodenal ulcer.
- Treatment with H 2 -anginadist or PPI suppresses gastric acid secretion, and its therapeutic effect is evaluated using an increase in gastric pH as an index.
- relapse of reflux esophagitis is a rebound phenomenon due to discontinuation of medication such as H2-angigonist and PPI, and this is considered to be predictable to some extent by measuring gastric pH.
- gastric pH By measuring gastric pH in this way, there is a therapeutic effect and side effects of the drug. It will be possible to predict the degree. In addition, intragastric pH measurement is considered to be widely applicable to the evaluation of therapeutic effects and the diagnosis of diseases.
- a currently known method for measuring gastric pH is to administer a formulation containing vitamin B2 in gastric-soluble capsules to subjects, and then measure the concentration of vitamin B2 excreted in urine by HPLC.
- To determine the intragastric pH G-Test: J. Parm. Dyn., 7, 656-664 (1984)
- an endoscope with a pH measurement electrode attached to the tip of the subject There is a method of directly measuring the pH in the stomach by entering the stomach (Digestive Disease and Sciences, Vol. 42, No. 11 (1997)).
- the former method cannot accurately measure gastric pH due to other factors such as metabolism, and the latter method is painful to the subject because the endoscope is inserted directly into the stomach.
- An object of the present invention is to provide a preparation capable of simply and noninvasively measuring pH in the stomach. More specifically, an object of the present invention is to provide a preparation capable of measuring and evaluating gastric pH using exhaled breath. Another object of the present invention is to provide a simple method for measuring gastric stomach content using the preparation.
- the 1 C compound was prepared in a dosage form that dissolves depending on the p H formulation test subjects, such as human by oral administration, a certain relationship between the excretion behavior of 1 3 C behavior of the compound varies, gastric [rho Eta and labeled compounds released in response to p H in the stomach vitro I found something. Then, it was confirmed that the tendency of intragastric ⁇ can be measured and evaluated by measuring the body and excretion behavior of the 13 C compound.
- the present invention has been completed based on such findings.
- the present invention is a preparation for measuring gastric pH described in 1 to 9 below:
- a preparation for measuring gastric glucose content which is obtained by coating a composition containing a compound labeled with an isotope with a ⁇ -dependent soluble base.
- Isotope 1 3 C, 1 4 C, 1 5 N and 1 8 O is selected from the group consisting of gastric p H measuring preparation of 1, wherein at least one or Ruizure.
- the compound labeled with an isotope is at least selected from the group consisting of sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, ammonium carbonate, potassium bicarbonate, sodium hydrogen carbonate, and ammonium bicarbonate.
- the preparation for measuring intragastric pH according to 3 which is one kind.
- composition containing the compound labeled with the isotope is, in addition to the compound labeled with the isotope, at least one acid compound selected from the group consisting of citric acid, tartaric acid, and malic acid 5.
- the pH-dependent soluble base is at least one selected from the group consisting of methyl methacrylate, butyl methacrylate, dimethylaminoethyl methacrylate copolymer, and polyvinyl acetal getyl acetate.
- the preparation for gastric pH measurement described in 7 which is a gastrosoluble base.
- PH-dependent solubilizers include hydroxypropyl methylcellulose monophthalate, methacrylic acid-methyl methacrylate copolymer, hydroxypropylmethylcellulose acetate succinate, carboxymethylethylcellulose, and hydroxy.
- these preparations are available in oral forms such as ⁇ lj, capsules, pills, powders or granules. It has a dosage form for administration.
- the present invention also relates to a method for measuring gastric pH using any of the above-mentioned preparations for measuring gastric pH, and specifically includes the methods listed in the following 10 to 14:
- a method for measuring gastric pH which comprises orally administering the preparation for measuring gastric pH described in 1 above to a subject and measuring the excretion behavior of the labeled compound from the body.
- the preparation for gastric pH measurement according to any of 1 to 9 above is orally administered to a subject suspected of decreasing or increasing gastric pH, and the excretion behavior of the labeled compound obtained after a predetermined time is compared with that of the standard control.
- a method for measuring the gastric pH of the subject comprising comparing.
- the present invention relates to the use of any of the above-mentioned preparations for measuring gastric pH in the stomach;
- the compound labeled with an isotope is an alkali metal salt of carbonic acid or hydrogen carbonate, an alkaline earth metal salt or an ammonium salt.
- the gastric pH measurement in the present invention is not limited to the meaning of measuring a specific pH value in the stomach, but is a measure of pH tendency in the stomach. Differentiating between various cases based on gastric pH, such as hyperplasia, normal, hypoxia, and anhydrosis It encompasses a wide range of meanings as judged. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a diagram showing the results of Example 1. That is, the enteric capsule of the present invention was used as a hypoxia model animal (indicated by- ⁇ -) and a normal acid model animal (- ⁇ in the figure)
- Shown by —. 2 shows the results of tracking the difference ( ⁇ )) in the ratio of carbon dioxide 1 ⁇ cc ⁇ z 12 c ⁇ 2 in exhaled air with time.
- the preparation for measuring intragastric pH of the present invention is characterized in that it has a form in which a composition containing a compound labeled with an isotope is coated with a pH-dependent soluble base.
- the compound labeled with the isotope here is orally administered to the subject, and then dissolved in the subject's body, and in some cases, is decomposed or metabolized, and the exhaled breath and body fluids (urine, blood, saliva, sweat, etc.) There is no particular limitation as long as it is excreted in the human body.
- the compound appears as a carbon dioxide gas promptly in the breath after dissolution in vivo, dissolved to carbonate ions (C0 3 _ 2) or bicarbonate (HC0 3 _1) can be mentioned wide-generating compounds, for example, carbonate Alkali metal salts of carbonic acid such as sodium and potassium carbonate: Al carbonic acid such as calcium carbonate and magnesium carbonate Lithium metal salts: ammonium carbonate; alkaline metal salts of hydrogen carbonate such as potassium bicarbonate, sodium bicarbonate and the like: ammonium bicarbonate, etc.
- acid conjugates such as citric acid, tartaric acid, malic acid, etc.
- these compounds can quickly appear as carbon dioxide in breath.
- it is sodium carbonate, potassium carbonate, sodium hydrogen carbonate, or potassium hydrogen carbonate.
- Compounds that appear as carbon dioxide in breath after being dissolved, decomposed, or metabolized in vivo include amino acids, proteins, organic acids or salts thereof (eg, alkali metal salts such as Na), saccharides, and lipids And the like. All of these release carbon dioxide into the exhaled breath after digestion and absorption, and by metabolism.
- amino acids include glycine, phenylalanine, tributofan, methionine, valine, and histidine: organic acids such as acetic acid, lactic acid, pyruvic acid, butyric acid, propionic acid, octanoic acid, and alkali metal salts thereof:
- the saccharide include glucose, galactose, xylose, and lactose;
- examples of the lipid include medium-chain triglycerides such as trioctanoin, but are not limited thereto.
- amino acids such as daricin
- organic acids such as acetic acid and octanoic acid
- alkali metal salts thereof sodium salt and potassium salt
- the isotope labeling such compounds include 1 3 C, 1 4 C, 1 ⁇ ⁇ and 1 8 0 like.
- the isotope may be radioactive or non-radioactive, but is preferably a non-radioactive isotope from the viewpoint of safety.
- a isotope 1 3 C, 1 5 N, 1 8 ⁇ and the like, suitable for may be mentioned 1 3 C.
- the method of labeling with these isotopes is not particularly limited, and commonly used methods are widely adopted.Also, those which are known as labeled compounds labeled with these isotopes and those which are commercially available (Sasaki, “5.1 Application of stable isotopes to clinical diagnosis”: Chemistry 107 “Application of stable isotopes to medicine, pharmacy, and biology” pp.149 ⁇ 163 (1975) Nankodo; Kajiwara, RADIOISOTOPES, 41, 45-48 (1992), etc.).
- the intragastric pH measurement preparation of the present invention is prepared by coating the above-mentioned isotope-labeled compound or a composition containing the same with a pH-dependent soluble base.
- the mode of coating with a pH-dependent soluble base is such that, when a preparation for measuring gastric pH is orally administered to a subject, the base is first dissolved depending on the pH in the living body of the subject, and then the base is dissolved.
- the isotope-labeled compound is designed to dissolve with or after dissolution of the compound.
- isotope-labeled compounds prepared in various forms such as powder, granules, tablets, and pills, or compositions containing the same (hereinafter, these are collectively referred to as “labeled compounds”)
- Ingredients '' and ⁇ ) are coated in the form of a coating, and the pH-dependent dissolution of the labeled compound-containing material of any shape such as powder, granule, liquid, semi-solid, etc.
- the capsule and the like included in the capsule base formed of the active base can be exemplified.
- these coating methods can be performed according to a conventional method.
- the pH-dependent soluble base used in the present invention includes a gastric-soluble base and an enteric base.
- a gastric-soluble base refers to a base that is generally soluble in the stomach pH of healthy subjects or those with hyperacidity, specifically a base that dissolves at pH 5 or lower, and specifically, aminoacryl methacrylate.
- Methyl methacrylate / butyl methacrylate 'dimethylaminoethyl methacrylate copolymer such as copolymer E (trade name: Eudragit E 100, manufactured by Laem Pharma Co., Ltd.), polyvinyl acetate, dimethyl acetyl acetate (trade name: AEA And Sankyo Co., Ltd.).
- An enteric base is a weak alkaline state generally observed in the stomach pH of hypoxic and anhydric patients, specifically a base that dissolves at pH 5 or higher.
- hydroxypropyl methylcellulose phthalate (trade name: HP-55 or HP-50, manufactured by Shin-Etsu Chemical Co., Ltd.)
- methyl methacrylate-methyl methacrylate methyl copolymer (trade name: Eudragit S100) Acrylate copolymer or methacrylate acrylate copolymer, hydroxypropylmethylcellulose acetate succinate (trade name: AQ @ AT, Shin-Etsu Chemical Co., Ltd.)
- carboxymethyl ester Enteric polymers such as chill cellulose, hydroxypropyl methylcellulose monofluorate and cellulose acetate fluorate can be exemplified.
- the preparation for measuring intragastric pH of the present invention is designed to exhibit a dissolution behavior according to the intended use.
- a formulation using a gastric-soluble base that dissolves at pH 4 or less as a pH-dependent soluble base.
- an amino acrylmethacrylate copolymer E can be preferably exemplified.
- a preparation When used for diagnosis / determination of hypoxia or anoxia, it is preferable to formulate a preparation using an enteric base that dissolves at pH 6 or more as a PH-dependent soluble base.
- Suitable examples of the enteric base include hydroxypropyl methylcellular monophthalate (trade name: HP-55, manufactured by Shin-Etsu Chemical Co., Ltd.).
- HP-55 hydroxypropyl methylcellular monophthalate
- the gastric pH can be measured.
- 1 3 C-labeled compounds C e.g. N a H 1 3 C_ ⁇ 3
- gastric formulations to a composition comprising as a main raw material coated with stomach-soluble base, traces 1 4.
- Enteric the compound eg if C compound-containing composition comprising a N a H 1 4 CO was coated with an enteric base Sex formulation, the combination is administered orally at the same time, after a certain time, when the gastric p H is in Hypochlorhydria tendency, only 1 4 C compounds is detected is released into the outside or body fluids, whereas stomach If the internal pH is prone to hyperacidity, only the 1 QC compound is released outside the body or into body fluids and detected. Further, if the moderate acidity in the stomach, any of 1 3 C of compound and 1 4 C compounds not detected.
- isotopically labeled compounds e.g., in the above case 1 C compound and 1 C compound
- Ru acidic tendency der force also in the middle It is possible to measure specifically whether there is.
- gastric pH by combining a urine excretion test and a breath test.
- enteric 1 C compound formulation stomach-soluble vitamin B 2 preparation and example, the present invention, by measuring the amount of ⁇ U C_ ⁇ 2 vitamin B 2 concentration in the breath of urine
- the gastric pH can be evaluated comprehensively.
- the form of the preparation for pH measurement of the present invention is not particularly limited as long as it is solid, and may be any of tablets, pills, granules, powders, and capsules.
- the form of the pharmaceutical composition contained therein is not particularly limited as long as the capsule base is composed of a pH-dependent soluble base, and may be liquid or semi-liquid. Or a solid material such as granules or powder.
- the amount of the labeled compound-containing substance contained in the preparation for pH measurement of the present invention is not particularly limited, but is usually 1 to 500 mg / unit dose, preferably 1 to 500 mg / unit dose, from the viewpoint of ease of administration. It can be appropriately selected from the range of 0 to 50 O mg.
- the proportion of the isotope-labeled compound contained in the preparation for pH measurement of the present invention varies depending on the type of the isotope used, but when a non-radioactive isotope is used, it is usually 1 to 200 mg. Is preferably from 0.1 to LOCi, preferably from 0.5 to 4 Ci, when a radioisotope is used. Further, the mixing ratio of the pH-dependent soluble base used for coating the labeling compound-containing substance is 5 to 100 parts by weight, preferably 30 to 50 parts by weight, per 100 parts by weight of the labeling compound-containing substance. Examples can be given.
- the present invention is also a gastric pH measurement method using the aforementioned gastric pH measurement preparation.
- the preparation for measuring intragastric pH of the present invention containing an isotope-labeled compound is orally administered to subjects such as animals and humans, and exhaled breath, urine, stool, blood or other body fluid, preferably
- a biological sample such as breath, urine, or stool, more preferably, breath is collected, and the amount of the label excreted in the collected biological sample is compared with the amount in the biological sample before administration, and is compared with the amount in the body or body. It can be performed by examining the excretion behavior and comparing the behavior with a standard control.
- Examples of the standard control include, but are not limited to, a conventionally known gastric pH measurement method (GA-Test: J. Pharm. Dyn., 7, 656-664 (1984); Digestive Disease and Sciences, Vol. .42, No.11 (1997)), a standardized data obtained by investigating a certain correlation between the intragastric pH measured by the method of the present invention and the intragastric pH measured by the method of the present invention can be used. .
- G-Test J. Pharm. Dyn., 7, 656-664 (1984); Digestive Disease and Sciences, Vol. .42, No.11 (1997)
- the standard 1 C breath test method Kajiwara, RADIOISOTOPES, 41, 45-48 (1992); Kajiwara et al., RADIOISOTOPES, 41, accordance 331-334 (1992), etc.
- the gastric pH measurements titration the formulation of the present invention following oral administration to a subject, with time collected breath, 1 3 C_ ⁇ discharged during exhalation.
- the amount as the 1 SccuZ 1 2 CO single amount (S 13 C value), the time it criteria 1 3 cc ⁇ / 1 2 C_ ⁇ 2 weight before administration and (s 13 c value) and compared over time By measuring such behavior and comparing the behavior with a standard control, the tendency of the subject's gastric pH can be evaluated.
- the preparation for measuring intragastric pH of the present invention can be prepared by dissolving a carbonate ion or bicarbonate as an isotope-labeled compound such as a salt of carbonic acid or bicarbonate (eg, an alkali metal salt, an alkaline earth metal salt, or an ammonium salt).
- a carbonate ion or bicarbonate as an isotope-labeled compound such as a salt of carbonic acid or bicarbonate (eg, an alkali metal salt, an alkaline earth metal salt, or an ammonium salt).
- a compound that generates ions is used, it is less susceptible to physiological factors such as absorption and metabolism, so that the measurement can accurately reflect the pH in the stomach.
- the gastric DH was evaluated only once using the pH measurement preparation of the present invention. However, by repeating the procedure several times, it is also possible to combine multiple preparations prepared using coating bases (gastric-soluble bases, enteric bases) with different pH-dependent solubility as pH-dependent soluble bases.
- the measurement and analysis of the label contained in the collected biological sample differs depending on whether the isotope used for labeling is radioactive or non-radioactive.However, liquid scintillation counter method, mass spectrometry, infrared spectroscopy, The analysis can be performed using a commonly used analysis method such as an emission analysis method or a magnetic resonance spectrum method. Preferred are infrared spectroscopy and mass spectrometry from the viewpoint of measurement accuracy.
- the administration method and administration time of the preparation for measuring intragastric pH of the present invention are not particularly limited.
- the administration is performed on an empty stomach, which is not affected by diet.
- the amount of the isotope-labeled compound to be incorporated into the dosage unit form of the preparation for intragastric pH measurement of the present invention varies depending on the sample to be measured, the type of the isotope used, and the type of the isotope-labeled compound. Can not be set, and can be adjusted and set appropriately according to the case. For example, using a 1 3 labeled sodium hydrogen comprising at C as isotopically labeled compounds (N a H 1 3 C_ ⁇ 2), when measured by the breath test, the gastric p H for measurement preparation per unit dose sodium bicarbonate (N a H 1 ° C 0 2) 1-2 0 0 0:11 8, preferably it is desirable to include in the range of 1 0 to 2 0 O mg.
- the coating base on the surface of the formulation first dissolves due to the effect of the pH in the living body, and then the internal isotope-labeled compound starts to elute.
- isotopically labeled compounds as labeled carbon dioxide
- gastric base which generally dissolved in intragastric p H it label in case of the coated comprising formulation was administered to the subject, is accompanied connexion labeled compounds N a H 1 3 CO 3 to dissolve the stomach-soluble base was eluted in the stomach, the companion connexion sequentially during expiration to the dissolution carbonated gas 1 3 C_ ⁇ 2 is excreted.
- the 1 3 C 0 2 gas excreted behavior (specifically in breath, for example, the proportion of 1 3 C_ ⁇ 2 gas or carbonated gas 1 2 Ji ⁇ 2 ⁇ excreted in breath [13 C0 2 Z 12 shown as C0 2]) shows a 1 3 C_ ⁇ 2 gas excreted behavior peculiar depending on intragastric p H of test subjects.
- the stomach above When using a preparation coated with soluble base, who intragastric p H as the patient's gastric hyperacidity is ruled low ratio the 13 C0 2 gas excreted behavior in human normal gastric pH is and there is high tendency, whereas, those intragastric pH as the patient's Hypochlorhydria or achlorhydria is that on the rise, the 13 C_ ⁇ 2 gas excreted behavior in humans with normal gastric p H They tend to be slower.
- the amount of 13 CO 2 gas increases with time.
- Value by measure the difference) between the d 13 C values in breath before administration the breath 13 C0 2/12 C0 2 concentration ratio at each sampling ( ⁇ 5 13 C value after administration)
- the presence or absence of a decrease or increase in gastric pH can be evaluated.
- the gastric pH measurement method of the present invention can be rephrased as a method of diagnosing and evaluating the presence or absence of a decrease or increase in gastric pH.
- the labeled conjugate is an organic acid, such as an acid, or an amino acid, such as glycine
- it is dissolved and absorbed in the intestine after excretion from the stomach, and then metabolized as hepatic metabolite. Since it appears in the exhaled breath, its detection (exhaled excretion of labeled carbon dioxide 13 co 2 ) is slower than in the above case, but since the rate-limiting step is the dissolution of the coating base, the above NaH 13 C ⁇ 3 Similarly to the compounds such as these, it is possible to evaluate the presence or absence of a decrease in gastric pH and an increase in Z.
- the intragastric pH measurement method of the present invention is useful in that it is a method for non-invasively and easily evaluating and diagnosing intragastric pH by collecting a small number of breaths without restraining the subject for a long time.
- the gastric pH measurement method of the present invention it is possible to evaluate the therapeutic effect on diseases related to gastric pH, or the drug effect or therapeutic effect of drugs related to gastric pH.
- the evaluation was performed before and after administration of the drug to the subject,
- the measurement can be performed by measuring the intragastric pH using the preparation for measurement and comparing the two.
- This makes it possible to evaluate the drug efficacy of the administered drug and to evaluate the therapeutic effect of each drug on the subject, and as a result, use it as a means to select drugs that are suitable for each subject.
- As the drug compound related to the gastric pH proton pump inhibitors (PP I) or as in such as H 2 blockers, it may be mentioned drug having an action of increasing gastric pH.
- PP I proton pump inhibitors
- H 2 blockers it may be mentioned drug having an action of increasing gastric pH.
- a normal gastric acid model animal was prepared by collecting exhaled air before administration of the capsule of the present invention and then forcibly administering 0. IN HC1 by 2 Oml. Next, capsules were immediately orally administered to the normal gastric acid model animal by forced oral administration, and exhaled air was collected over time.
- hypoxia model animals were prepared by collecting exhaled breath before administration of the capsule of the present invention and then forcibly administering an H 2 antagonist (famotidine hydrochloride 10 mg). Then, into H 2 antagonist administered 1 hour after the The capsule of the present invention was forcibly orally administered to a hypoxia model animal, and exhaled air was collected over time.
- H 2 antagonist famotidine hydrochloride 10 mg
- GC-MS (ABCA- G, Europa Scientific Inc.) using a pre-given capsules throw of the present invention, 1 3 C0 2 / i 2 C0 2 concentration ratio in the breath of the breath sampling point after administration ([delta] 1 3 C value) was measured, delta values from the difference between [delta] 1 3 C value before the administration [delta] 1 3 C value and the formulation of each sampling points after administration of the formulation. ) ( ⁇ 1 3 C value after formulation administration - were calculated [delta] 1 ° a preformulation administration.
- the hypoxia model animal reached the peak arrival time (TMX) at 1 hour
- the normal acid model animal reached Tmax at 2.7 hours
- the hypoxia model animal and a large difference was found in the 3 C0 2 exhalation discharge behavior between normal acid model animal. From these results, according to the preparation for measuring intragastric pH of the present invention, it is possible to monitor the pH in the stomach. In particular, there is a significant difference between the low acid tendency and the normal acid tendency in the stomach and the gastric hyperacidity tendency. It was also found that it could be identified and evaluated.
- NaHl 3 C ⁇ 3 (10 Omg) was added to an enteric capsule base (Japanese Pharmacopoeia No. 1 capsule (6 Omg), hydroxypropyl methylcellulose phthalate, trade name: HP-55, Shin-Etsu Chemical Co., Ltd. (pH 5. 5 or more)) to prepare an enteric-coated preparation for intragastric pH measurement (capsule 1).
- NaH 1 ⁇ J C10 3 (10 Omg) was used in the same manner as a gastric-soluble capsule base (Japanese Pharmacopoeia No.
- exhaled air was collected before administration of the preparation of the present invention, and then capsule 1 was forcibly administered orally, and exhaled air was collected over time. Then, after a one-week drug holiday, breaths are collected before administration of the preparation of the present invention in the same manner as above, and capsule 2 is forcibly administered orally, and breaths are collected over time. did.
- Fig. 2 shows the exhalation excretion pattern of four beadal dogs after administration of the forcepsel agent
- Fig. 3 shows the exhalation excretion pattern of four bidal dogs after administration of the capsule agent 2.
- Hydroxypropylcellulose (HPC-L: Shin-Etsu Chemical) 7.5 mg
- the pH or the tendency of the pH in the stomach of a human or animal can be easily and accurately determined. Can be measured and evaluated.
- the preparation for intragastric pH measurement prepared using a labeled compound excreted as labeled carbon dioxide gas in exhaled breath, the subject does not put a mental or physical burden on the subject, and the stomach is easily subjected to the B $ qi test. PH or its tendency can be measured.
- the preparation for measuring gastric pH of the present invention and the method for measuring gastric pH using the same it is possible to easily and accurately diagnose and evaluate whether the pH of the subject has decreased or increased in the stomach. It is possible to Furthermore, by using the preparation for measuring gastric pH of the present invention and the method for measuring gastric pH using the same, the diagnosis and treatment effect of diseases related to gastric pH and the medicinal effects of drugs related to gastric pH can be obtained. It is possible to make an evaluation judgment directly and easily.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Atmospheric Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002503346A JP4748917B2 (ja) | 2000-06-21 | 2001-06-21 | 胃内pH測定用製剤及びそれを用いた胃内pH測定法 |
AU2001274585A AU2001274585B2 (en) | 2000-06-21 | 2001-06-21 | Preparations for measuring gastric pH value and method of measuring gastric pH value by using the same |
CA002413254A CA2413254A1 (en) | 2000-06-21 | 2001-06-21 | Preparations for measruing gastric ph value and method of measuring gastric ph value by using the same |
US10/312,266 US20030129131A1 (en) | 2000-06-21 | 2001-06-21 | Preparations for measuring gastric ph value and method of measuring gastric ph value by using the same |
EP01941167A EP1312381A4 (en) | 2000-06-21 | 2001-06-21 | PREPARATIONS FOR MEASURING THE GASTRIC pH AND METHODS FOR MEASURING THE GASTRIC pH BY USE THEREOF |
AU7458501A AU7458501A (en) | 2000-06-21 | 2001-06-21 | Preparations for measruing gastric ph value and method of measuring gastric ph value by using the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-186589 | 2000-06-21 | ||
JP2000186589 | 2000-06-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001097863A1 true WO2001097863A1 (en) | 2001-12-27 |
WO2001097863A8 WO2001097863A8 (fr) | 2003-02-13 |
Family
ID=18686722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005331 WO2001097863A1 (en) | 2000-06-21 | 2001-06-21 | PREPARATIONS FOR MEASURING GASTRIC pH VALUE AND METHOD OF MEASURING GASTRIC pH VALUE BY USING THE SAME |
Country Status (6)
Country | Link |
---|---|
US (1) | US20030129131A1 (ja) |
EP (1) | EP1312381A4 (ja) |
JP (1) | JP4748917B2 (ja) |
AU (2) | AU2001274585B2 (ja) |
CA (1) | CA2413254A1 (ja) |
WO (1) | WO2001097863A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009145284A (ja) * | 2007-12-18 | 2009-07-02 | Toto Ltd | 健康状態測定装置および測定方法 |
JP2009145190A (ja) * | 2007-12-14 | 2009-07-02 | Toto Ltd | 二酸化炭素ガス測定装置およびこの装置を内包する健康状態測定装置 |
WO2012023590A1 (ja) * | 2010-08-19 | 2012-02-23 | 大塚製薬株式会社 | 13c炭酸塩を用いた胃内酸度の定量的測定方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943179B2 (en) * | 2003-09-23 | 2011-05-17 | Massachusetts Institute Of Technology | pH triggerable polymeric particles |
US20050123596A1 (en) * | 2003-09-23 | 2005-06-09 | Kohane Daniel S. | pH-triggered microparticles |
CA2882528A1 (en) | 2012-08-20 | 2014-02-27 | Otsuka Pharmaceutical Co., Ltd. | Method for measuring carbohydrate metabolism ability, and composition for use in said method |
CN107595793B (zh) * | 2012-11-30 | 2020-11-13 | 阿库拉制药公司 | 活性药物成分的自调节释放 |
KR20210014204A (ko) | 2013-03-15 | 2021-02-08 | 오츠카 세이야쿠 가부시키가이샤 | 지방산 연소에 의한 인슐린 저항성의 측정 방법, 및 그에 사용하는 조성물 |
CN104940961B (zh) * | 2015-07-07 | 2017-10-17 | 上海交通大学医学院附属瑞金医院 | 一种胃内pH检测微丸及其用途 |
WO2018097222A1 (ja) * | 2016-11-25 | 2018-05-31 | 大塚製薬株式会社 | 栄養状態の評価方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07300430A (ja) * | 1994-04-29 | 1995-11-14 | Akira Torii | 胃排出機能検査剤 |
WO1996014091A1 (en) * | 1994-11-02 | 1996-05-17 | Diabact Ab | Diagnostic preparation for detection of helicobacter pylori |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020107211A1 (en) * | 1995-06-07 | 2002-08-08 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
JP2768559B2 (ja) * | 1994-11-02 | 1998-06-25 | ダイアバクト・エイ・ビー | ヘリコバクテル・ピロリ(Helicobacter Pylori)の検出のための診断用調剤 |
US6294151B1 (en) * | 1996-08-13 | 2001-09-25 | Kyowa Hakko Kogyo, Co., Ltd. | Isotopic urea tablets |
CA2409223A1 (en) * | 2000-05-02 | 2002-11-18 | Otsuka Pharmaceutical Co., Ltd. | Preparations for evaluating eliminative ability of stomach |
-
2001
- 2001-06-21 CA CA002413254A patent/CA2413254A1/en not_active Abandoned
- 2001-06-21 AU AU2001274585A patent/AU2001274585B2/en not_active Ceased
- 2001-06-21 EP EP01941167A patent/EP1312381A4/en not_active Withdrawn
- 2001-06-21 WO PCT/JP2001/005331 patent/WO2001097863A1/ja not_active Application Discontinuation
- 2001-06-21 AU AU7458501A patent/AU7458501A/xx active Pending
- 2001-06-21 JP JP2002503346A patent/JP4748917B2/ja not_active Expired - Fee Related
- 2001-06-21 US US10/312,266 patent/US20030129131A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07300430A (ja) * | 1994-04-29 | 1995-11-14 | Akira Torii | 胃排出機能検査剤 |
WO1996014091A1 (en) * | 1994-11-02 | 1996-05-17 | Diabact Ab | Diagnostic preparation for detection of helicobacter pylori |
Non-Patent Citations (1)
Title |
---|
See also references of EP1312381A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009145190A (ja) * | 2007-12-14 | 2009-07-02 | Toto Ltd | 二酸化炭素ガス測定装置およびこの装置を内包する健康状態測定装置 |
JP2009145284A (ja) * | 2007-12-18 | 2009-07-02 | Toto Ltd | 健康状態測定装置および測定方法 |
WO2012023590A1 (ja) * | 2010-08-19 | 2012-02-23 | 大塚製薬株式会社 | 13c炭酸塩を用いた胃内酸度の定量的測定方法 |
JP2016200603A (ja) * | 2010-08-19 | 2016-12-01 | 大塚製薬株式会社 | 13c炭酸塩を用いた胃内酸度の定量的測定方法 |
JP2018066742A (ja) * | 2010-08-19 | 2018-04-26 | 大塚製薬株式会社 | 13c炭酸塩を用いた胃酸抑制剤の薬効測定方法 |
Also Published As
Publication number | Publication date |
---|---|
US20030129131A1 (en) | 2003-07-10 |
AU2001274585B2 (en) | 2005-09-15 |
EP1312381A4 (en) | 2004-12-22 |
JP4748917B2 (ja) | 2011-08-17 |
WO2001097863A8 (fr) | 2003-02-13 |
AU7458501A (en) | 2002-01-02 |
EP1312381A1 (en) | 2003-05-21 |
CA2413254A1 (en) | 2002-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Akiyama et al. | Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites | |
US20060153771A1 (en) | Preparations for measuring gastric emptying ability | |
ES2529455T3 (es) | Sistema de administración de fármacos por dosis controladas | |
JP2012514623A (ja) | 1またはそれ以上のフマル酸エステルを含む医薬組成物 | |
JP6538140B2 (ja) | 13c炭酸塩を用いた胃酸抑制剤の薬効測定方法 | |
AU2016398029B2 (en) | Palatable compositions including sodium phenylbutyrate and uses thereof | |
JP4748917B2 (ja) | 胃内pH測定用製剤及びそれを用いた胃内pH測定法 | |
Wilding et al. | Characterisation of the in vivo behaviour of a controlled-release formulation of levodopa (Sinemet CR) | |
JP2008534621A (ja) | リオチロニンからなる放出制御型医薬組成物、並びにその製造方法及び使用方法 | |
JP4091660B2 (ja) | 診断用組成物 | |
WO2016006601A1 (ja) | 肝疾患被験者のエネルギー低栄養評価 | |
ES2488412T3 (es) | Agente de ensayo para el diagnóstico de la dispepsia | |
JP4683812B2 (ja) | ヘリコバクター・ピロリ感染の診断用製剤 | |
Krishna et al. | Strategic Approaches and Evaluation of Gastro Retentive Drug Delivery system-A Review | |
JP5770997B2 (ja) | Cyp3a4の代謝機能測定方法 | |
Hodges | In Vivo Characterization of Oral Multiparticulate Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2413254 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10312266 Country of ref document: US Ref document number: 2001274585 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001941167 Country of ref document: EP |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE |
|
WWP | Wipo information: published in national office |
Ref document number: 2001941167 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001274585 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001941167 Country of ref document: EP |